New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
13:25 EDTFLDM, FLDM, FLDM, GNOM, GNOM, GNOM, ILMN, ILMN, ILMN, LIFE, LIFE, LIFE, ONT, ONT, ONT, PACB, PACB, PACBLeerink's life science tools and diagnostics analyst to hold a conference call
Life Science Tools & Diagnostics Analyst Leonard provides an update on the DNA sequencing landscape including ILMN’s new HiSeq capability, LIFE’s Ion Proton and PGM, desktop sequencing demand and the funding environment for nextgen sequencing. Relevant companies FLDM, GNOM, ILMN, LIFE, ONT and PACB may be included on the Analyst/Industry conference call to be held on January 24 at 2 pm.
News For FLDM;GNOM;ILMN;LIFE;ONT;PACB From The Last 14 Days
Check below for free stories on FLDM;GNOM;ILMN;LIFE;ONT;PACB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
11:53 EDTPACBPacific Biosciences management to meet with Maxim
Subscribe for More Information
09:16 EDTPACBPacific Biosciences milestone payment shows Roche commitment, says Maxim
Maxim believes Roche's (RHHBY) milestone payment to Pacific Biosciences (PACB) indicates that the larger partner is committed to continuing the in vitro diagnostics program despite its recent acquisition and strategic investment with others. Maxim raised its 2014 revenue estimate for Pacific Biosciences to reflect the payment and recommends investors buy shares.
09:01 EDTPACBPacific Biosciences discloses achievement of development milestone
Subscribe for More Information
August 21, 2014
05:42 EDTILMNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
10:04 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:18 EDTILMNIllumina upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use